H-Index
38
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
call: +1.631.629.4327
Mon-Fri 10 am - 2 pm EST

Logo

MSMbanner
Medical Science Monitor Basic Research

AmJCaseRep
MedSciTechnol

eISSN: 2329-0358

Compliance and tolerability of subcutaneous hepatitis B immunoglobulin self-administration in liver transplant patients: A prospective, observational, multicenter study

Christian Georg Klein, Vito Cicinnati, Hartmut Schmidt, Tom Ganten, Marcus N. Scherer, Felix Braun, Stefan Zeuzem, Andrea Wartenberg-Demand, Gabriele Niemann, Rainer Schmeidl, Susanne Beckebaum

Department of General, Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany

Ann Transplant 2013; 18:677-684

DOI: 10.12659/AOT.889269

Available online: 2013-12-13

Published: 2013-12-13


#889269

Background: Subcutaneous self-administration of hepatitis B immunoglobulin (HBIg) prophylaxis is preferred by patients, but compliance with the assigned regimen in routine practice is undocumented.
Material and Methods: A prospective, observational, 18-week, open-label, single-arm, multicenter study assessed compliance and tolerability in maintenance liver transplant patients self-administering subcutaneous HBIg at home according to local practice.
Results: Sixty-one patients were analyzed (median follow-up 18 weeks, range 14.0–27.9 weeks), with 961/1006 injections (95.5%) administered at home during the study. Other than in 4 patients, HBIg was prescribed for weekly administration (500 IU/L, n=39; 1000 IU/L, n=18) at study entry. Eighteen patients (29.5%) were assigned a dose lower than recommended in the Summary of Product Characteristics. The primary variable of compliance failure, defined as ≥1 hepatitis B surface antibody (anti-HBs) serum trough level <100 IU/L, occurred in 4 patients (6.6%; 95% CI 1.8%, 15.9%), 3 of whom were receiving a dose below that recommended for their body weight. Anti-HBs levels exceeded 100 IU/L in all patients at the final visit. Mean (SD) anti-HBs level at the first and final study visits was 248 (97) IU/L and 255 (104) IU/L, respectively. Patient compliance was graded good or very good by physicians in 91.8% of cases. No patients tested positive for HBsAg or HBV-DNA. Four patients experienced ≥1 adverse drug reactions, none of which was serious. No patient discontinued HBIg due to adverse events.
Conclusions: Subcutaneous HBIg home-based self-administration under routine, real-life conditions is well-tolerated and associated with high compliance and maintaining protective anti-HBs serum concentration.

Keywords: Compliance, home, HBV, Subcutaneous, HBlg, self-injection



Back